CN112159799A - 一种NDVVIId突变型感染性克隆病毒DHN3-mF及其制备方法和疫苗 - Google Patents
一种NDVVIId突变型感染性克隆病毒DHN3-mF及其制备方法和疫苗 Download PDFInfo
- Publication number
- CN112159799A CN112159799A CN202010499879.4A CN202010499879A CN112159799A CN 112159799 A CN112159799 A CN 112159799A CN 202010499879 A CN202010499879 A CN 202010499879A CN 112159799 A CN112159799 A CN 112159799A
- Authority
- CN
- China
- Prior art keywords
- virus
- dhn3
- gene
- sequence
- rdnn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 97
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 30
- 230000002458 infectious effect Effects 0.000 title claims abstract description 20
- 229960005486 vaccine Drugs 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 32
- 101150041842 DHN3 gene Proteins 0.000 claims description 34
- 239000000243 solution Substances 0.000 claims description 33
- 239000013612 plasmid Substances 0.000 claims description 29
- 239000012530 fluid Substances 0.000 claims description 21
- 210000003837 chick embryo Anatomy 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 9
- 239000012124 Opti-MEM Substances 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 101150084044 P gene Proteins 0.000 claims description 7
- 230000008014 freezing Effects 0.000 claims description 7
- 238000007710 freezing Methods 0.000 claims description 7
- 238000001890 transfection Methods 0.000 claims description 7
- 239000012096 transfection reagent Substances 0.000 claims description 7
- 108010019160 Pancreatin Proteins 0.000 claims description 6
- 229940055695 pancreatin Drugs 0.000 claims description 6
- 101150062031 L gene Proteins 0.000 claims description 5
- 101150118742 NP gene Proteins 0.000 claims description 5
- 238000001976 enzyme digestion Methods 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 238000010257 thawing Methods 0.000 claims description 5
- 238000012408 PCR amplification Methods 0.000 claims description 4
- 238000003306 harvesting Methods 0.000 claims description 4
- 230000006801 homologous recombination Effects 0.000 claims description 4
- 238000002744 homologous recombination Methods 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000018120 Recombinases Human genes 0.000 claims description 3
- 108010091086 Recombinases Proteins 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 3
- 229940088598 enzyme Drugs 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 230000006798 recombination Effects 0.000 claims description 2
- 238000005215 recombination Methods 0.000 claims description 2
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 abstract description 11
- 241001465754 Metazoa Species 0.000 abstract description 10
- 231100000419 toxicity Toxicity 0.000 abstract description 9
- 230000001988 toxicity Effects 0.000 abstract description 9
- 230000001681 protective effect Effects 0.000 abstract description 7
- 230000028993 immune response Effects 0.000 abstract description 6
- 230000002829 reductive effect Effects 0.000 abstract description 3
- 206010064571 Gene mutation Diseases 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 48
- 241000711404 Avian avulavirus 1 Species 0.000 description 26
- 241000287828 Gallus gallus Species 0.000 description 19
- 235000013330 chicken meat Nutrition 0.000 description 19
- 101150034814 F gene Proteins 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 230000010076 replication Effects 0.000 description 12
- 210000002257 embryonic structure Anatomy 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 229940031551 inactivated vaccine Drugs 0.000 description 9
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 108020000999 Viral RNA Proteins 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000002238 attenuated effect Effects 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000003053 toxin Substances 0.000 description 8
- 231100000765 toxin Toxicity 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 208000010359 Newcastle Disease Diseases 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 210000004779 membrane envelope Anatomy 0.000 description 6
- 210000002845 virion Anatomy 0.000 description 6
- 101710181008 P protein Proteins 0.000 description 5
- 101710177166 Phosphoprotein Proteins 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000001018 virulence Effects 0.000 description 5
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 4
- 101150008820 HN gene Proteins 0.000 description 4
- 101710085938 Matrix protein Proteins 0.000 description 4
- 101710127721 Membrane protein Proteins 0.000 description 4
- 102100034574 P protein Human genes 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 4
- 210000003555 cloaca Anatomy 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000001784 detoxification Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 108060003393 Granulin Proteins 0.000 description 3
- 231100000645 Reed–Muench method Toxicity 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010024642 Listless Diseases 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 102000007982 Phosphoproteins Human genes 0.000 description 2
- 108010089430 Phosphoproteins Proteins 0.000 description 2
- 238000010357 RNA editing Methods 0.000 description 2
- 230000026279 RNA modification Effects 0.000 description 2
- 102000004389 Ribonucleoproteins Human genes 0.000 description 2
- 108010081734 Ribonucleoproteins Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005485 electric heating Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940088592 immunologic factor Drugs 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 208000017971 listlessness Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 240000004718 Panda Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18161—Methods of inactivation or attenuation
- C12N2760/18162—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明属于兽用生物制品技术领域,公开了一种基因VII型NDV突变型感染性克隆重组病毒DHN3‑mF,其序列如序列表SEQ ID NO:1所示。该病毒经过对F蛋白所对应的序列进行基因突变,使之毒性降低,但是同时保证动物产生强烈的保护性免疫反应。同时,本发明还提供了该病毒的制备方法以及基于该病毒制备的疫苗。
Description
技术领域
本发明涉及兽用生物制品技术领域,特别涉及一种NDVVIId突变型感染性克隆 病毒DHN3-mF及其制备方法和疫苗。
背景技术
新城疫(Newcastle disease,ND)是由新城疫病毒(Newcastle disease virus,NDV)引起的禽类高度接触性传染病,可导致呼吸系统、神经系统、消化道及内脏损伤,致死率可达100%。自1926年印度爪洼和英国新城相继爆发,新城疫在世界范围经历了四次大流行造成了世界范围的巨大经济损失。第三次大流行后,新城疫疫苗开始在世界范围内广泛接种,首先是II系La Sota疫苗,后来依据Mukteswar株、Clone 30株、Hitchner B1株、F株、ZJI株等研制的疫苗也逐渐投入使用。目前在我国使用的活苗主要有Ⅰ系、Ⅳ系、和克隆30弱毒苗,以及弱毒油乳剂灭活苗。
疫苗的广泛使用,有效抑制了新城疫在世界范围的大规模爆发。进入上世纪90年代,基因Ⅶ型NDV逐渐成为世界范围的主要流行毒株。由于免疫疫苗的基因型与流行株基因型不匹配经常引起地方性的新城疫爆发。自1999年Peeters等人首次通过反向遗传的方法构建出NDV的感染性克隆至今已20余年,新城疫病毒的反向操作已日趋成熟。
本发明所要解决的技术问题是:如何在保证动物产生强烈的保护性免疫反应的同时,降低新城疫病毒的毒性。
发明内容
本发明的目的在于提供一种基因VII型突变型感染性克隆重组病毒DHN3-mF,该克隆经过对F基因的突变,使之毒性降低,但是同时保证动物产生强烈的保护性免疫反应。
同时,本发明还提供了该病毒的制备方法以及基于该病毒制备的疫苗。
为了实现上述目的,本发明提供的技术方案是:一种基因VII型突变型感染性克隆重组病毒rDHN3-mF,其序列如序列表SEQ ID NO:1所示。
新城疫病毒为有囊膜,单股不分节负链RNA病毒。成熟的病毒粒子呈近球形,病毒直径为100~300nm。囊膜外有长约8nm的糖蛋白纤突,分别为F和HN蛋白。囊膜内含有长约17nm的核甘酸/核衣壳蛋白复合体(Ribonucleoprotein,RNP),由NP、P、L蛋白和病毒RNA组成。核衣壳蛋白复合体与囊膜之间以M蛋白相连,M蛋白是维持病毒空间结构的重要蛋白。其结构可参考图1。
NDV编码6种病毒蛋白,其基因组3’~5’端依次编码核衣壳蛋白NP(Nucleocapsidprotein)、磷蛋白P(Phosphate protein)、基质蛋白M(Matrix protein)、融合蛋白F(Fusion protein)、血凝素-神经氨酸酶蛋白HN(Hemagglutinin-Neuraminidase)和依赖RNA的RNA 聚合酶蛋白L(Large RNA-dependent RNA polymerase protein)(Yusoff etal.,2001)。
NP基因含有1747nt,编码区1470nt,编码分子质量约为53KD的NP蛋白。NP蛋白是组成RNP的主要蛋白,每个RNP中约含有2500个NP单体,每个单体与6nt结合并按照螺旋状排列形成中空的管道,将病毒RNA包裹在其中(Nath et al.,2020),以避免病毒 RNA被核酸酶降解。病毒一旦进入宿主细胞NP蛋白即刻解螺旋暴露出病毒RNA。病毒RNA 与P蛋白和L蛋白构成RNA聚合酶复合体,启动病毒RNA转录。
P基因含有1451nt,编码区1188nt,编码分子质量约为42KD的P蛋白。P蛋白含有多个磷酸化位点,其在病毒RNA复制和转录中具有重要作用。P基因也是NDV基因组中唯一一个可以编码多个蛋白的基因。P基因在484位碱基处含有一段保守的序列 UUUUU↓CCC,在转录的同时经过“RNA编辑”在此位点添加“G”或“GG”,翻译出两条多肽,形成V蛋白和W蛋白(Karsunke et al.,2019;Steward et al.,1993)。P蛋白与 V蛋白和W蛋白具有相同的N-末端氨基端,只是通过RNA编辑形成了不同的羧基端。
M基因含有1241nt,编码区(1143nt)编码分子量约为35KD~40KD的M蛋白。M蛋白为基质蛋白,对于支撑NDV的空间构型起到重要作用。L基因长约6703nt,编码区 (6615nt)编码分子量约为249KD的L蛋白。L蛋白是核衣壳蛋白之一,其主要功能是与 P蛋白共同组成RNA聚合酶复合体(Hamaguchi et al.,1983)调控病毒基因组的复制和转录。
与NDV感染性和毒力最密切相关的基因是F基因和HN基因。F基因含有1792nt,编码区(1662nt)编码553aa。F蛋白的分子量约为55KD。F蛋白是NDV的主要毒力因子 (Peeterset al.,1999),其112~117位氨基酸是裂解位点。NDV强毒株裂解位点氨基酸序列为112R/K-R-Q-K/R-R-F117,弱毒株的裂解位点氨基酸序列为 112G/E-K/R-Q-G/E-R-L117(Nagaiet al.,1976;Panda et al.,2004)。新城疫强毒株与弱毒株的区别之一是强毒株的裂解位点能够被更多种类的细胞表面裂解酶识别,从而能感染更多种类的宿主细胞。弱毒株上裂解位点对应的裂解酶分布较窄,因此能被弱毒株感染的细胞种类较少。弱毒株在入侵某些细胞时还需要其他的细胞因子协助。因此,NDV的裂解位点决定病毒感染细胞的毒性和适应性。F蛋白是跨膜蛋白,其N端以三聚体的形式暴露于病毒囊膜之外,C端在病毒粒子囊膜之内。一般情况下F蛋白以无活性的前体蛋白F0 存在于病毒粒子中。当HN蛋白与受体识别后,受体细胞表面的蛋白裂解酶将F0蛋白裂解成为F1和F2两种蛋白,F1和F2之间以二硫键相连。F蛋白裂解后进一步介导病毒囊膜与细胞膜融合,病毒核糖核蛋白复合物进入宿主细胞开始病毒复制的过程。
HN基因编码区大小因毒株的类型而异,其编码的HN蛋白的分子量因而不同。比较常见的HN蛋白有三种,分别含571aa,577aa或616aa,其分子量约在72~75KD之间。HN 基因是NDV的另一个重要的毒力相关基因,HN决定病毒的抗原性与嗜性(Huang et al., 2004)。HN上含有抗原表位,它与宿主细胞内的免疫因子结合激发免疫反应(Jarahian et al.,2009)。成熟的HN蛋白以四聚体纤突的形式存在于病毒粒子上(Yuan et al.,2011),其结构分为球状区,杆状区。杆状区包含跨膜区和胞内区。球状区含唾液酸识别位点和抗原位点。球状区的第二个唾液酸结合位点有促进细胞膜与病毒囊膜融合的作用(Zaitsev et al.,2004)。HN杆状区能够激活F蛋白的生物活性从而促进病毒囊膜与细胞膜融合(Gravel etal.,2003;Iorio et al.,2001)。
NDV的裂解位点是决定病毒细胞感染性和适应性的关键因素。F蛋白是跨膜蛋白,一般情况下F蛋白以无活性的前体蛋白F0存在于病毒粒子中。当HN蛋白与受体识别后,受体细胞表面的蛋白裂解酶将F0蛋白裂解成为F1和F2两种蛋白,F1和F2之间以二硫键相连。F蛋白裂解后进一步介导病毒囊膜与细胞膜融合,病毒核糖核蛋白复合物进入宿主细胞开始病毒复制的过程。因此将NDV强毒株裂解位点氨基酸序列改变为弱毒株的裂解序列可以改变病毒的细胞嗜性和适应性,从而降低病毒的感染力和致病性。
HN上含有抗原表位,它与宿主细胞内的免疫因子结合激发免疫反应(Jarahian etal., 2009)。成熟的HN蛋白以四聚体纤突的形式存在于病毒粒子上(Yuan et al.,2011),其结构分为球状区,杆状区。杆状区包含跨膜区和胞内区。球状区含唾液酸识别位点和抗原位点。球状区的第二个唾液酸结合位点有促进细胞膜与病毒囊膜融合的作用(Zaitsev etal.,2004)。HN杆状区能激活F蛋白的生物活性从而促进病毒囊膜与细胞膜融合(Gravel etal.,2003;Iorio et al.,2001)。因此保留HN基因不变就能维持原病毒的抗原性。
基于以上的原理,本方案特对于F基因进行相应的改造,使之产生突变。其更为具体的设计思路为:将DHN3 F基因编码区(DHN3的全基因组的序列可参考CN201910894754.9,一种针对II类VII型流行NDV株DHN3的感染性重组克隆方法中SEQ ID NO1)的第112~ 117位氨基酸由强毒的“R-R-Q-K-R-F”突变成弱毒的“G-R-Q-G-R-L”序列,将DHN3 F基因与第112~117位氨基酸对应的碱基序列由“AGGAGACAAAAACGCTTT”突变为“GGGAGACAGGGGCGCCTT”,而后者与La Sota株F基因112-117位氨基酸的碱基序列相同。
此外,本发明还公开了如上所述的VII型NDV突变型感染性克隆重组病毒rDHN3-mF的制备方法,包括如下步骤:
步骤1:将质粒pBR322-DHN3采用SmaI酶切,得到酶切后的质粒;
步骤2:采用引物change-F1-F、change-F1-R和change-F2-F、change-F2-R以质粒pBR322-DHN3为模板扩增目的片段,得到PCR扩增产物;
步骤3:将酶切后的质粒和PCR扩增产物在重组酶的作用下同源重组,获得含mF的质粒pBR322-mFDHN3;
其中,质粒pBR322-DHN3为人工重组得到的DHN3全基因组重组入载体质粒中得到全基因组表达载体;所述DHN3全基因组的序列如序列表SEQ ID NO:2;
引物change-F1-F的序列如序列表SEQ ID NO:3;
引物change-F1-R的序列如序列表SEQ ID NO:4;
引物change-F2-F的序列如序列表SEQ ID NO:5;
引物change-F2-R的序列如序列表SEQ ID NO:6;
步骤4:采用转染试剂转染BHK-21细胞获得含病毒DHN3-mF的病毒液;所述转染试剂包含pBR322-mFDHN3 4μg,pXJ40-NP 2.5μg,pXJ40-P 1.25μg,pXJ40-L 1.25μg,pXJ40-DE3 3μg;
其中,辅助质粒pXJ40-NP、pXJ40-P、pXJ40-L的目标片段分别为NP基因、P基因、 L基因,载体为pXJ40;
所述NP基因在序列表SEQ ID NO:2中位置为1-1591nt;P基因在序列表SEQ ID NO:2中位置为1925-3109nt;L基因在序列表SEQ ID NO:2中位置为8166-15192nt。
在上述的基因VII型NDV突变型感染性克隆重组病毒rDHN3-mF的制备方法中,所述步骤1具体为:用SmaI酶切质粒pBR322-DHN3,通过0.8%琼脂糖凝胶电泳回收酶切后的质粒待用,酶切后的质粒的大小为13399bp。
在上述的基因VII型NDV突变型感染性克隆重组病毒rDHN3-mF的制备方法中,所述步骤3具体为:将BHK-21细胞培养于6孔板中,次日细胞长至80%左右满,转染前30min 用PBS清洗细胞3次,最后一次弃除PBS后每孔加入1ml Opti-MEM,将6孔板放回37℃ 5%CO2培养箱中继续培养,同时用赛默飞Lipofectamine LTX DNA Transfection Reagents转染试剂按照试剂说明配制如下转染液:
A液:Opti-MEM Medium 150μl,Lipofectamine LTX Reagent 15μl,静置5min;
B液:Opti-MEM DNA 175μl其中pBR322-mFDHN3 4μg,pXJ40-NP 2.5μg, pXJ40-P1.25μg,pXJ40-L 1.25μg,pXJ40-DE3 3μg,PLUS Reagent 3.5μl,吹打混匀,静置5min;
取A液,B液各150μl混合均匀,静置20min得到混合液;
取250μl混合液加入细胞培养液中,轻轻混匀,置37℃5%CO2培养,8h后弃除培养液,用PBS清洗3次后加含5%SPF鸡胚尿囊液和0.1%胰酶的DMEM培养液继续置 37℃5%CO2培养,4天后收获细胞置-80度冻存,在使用时,进行多次冻融后离心取上清液即可得到所述含病毒DHN3-mF的病毒液。
最后,本发明还公开了一种疫苗,含有灭活的如上所述的基因VII型NDV突变型感染性克隆重组病毒rDHN3-mF的制备方法。
本发明的有益效果在于:
本发明在rDHN3感染性克隆的基础上进行了F基因修改,通过基因编辑重建了一株在 F基因上修改了的pDNH3-mF感染性克隆,并成功获得了重组病毒rDNH3-mF。动物毒性实验证明该病毒比原毒株DHN3毒力明显减弱,按毒力标准划分属弱毒型。动物保护性实验证明该病毒能产生强烈的保护性免疫反应,能诱导产生高达效价的保护性抗体,并能100%保护动物不发病不排毒。
附图说明
图1为新城疫病毒的结构。
图2为本发明的pBR322-mFDHN3质粒构造图;
图3为BHK-21细胞感染rDHN3-mF病毒和DHN3病毒后的显微镜图;
图4为F基因片段测序结果;
图5为rDHN3-mF在BHK-21细胞中的复制曲线图;
图6为原毒DHN3在BHK-21细胞中的复制曲线图;
图7为原毒重组病毒rDHN3在BHK-21细胞中的复制曲线图;
图8为鸡强毒组接毒3天后感染后的器官病变图;
图9为鸡弱毒组接毒7天后感染后的器官病变图。
具体实施方式
下面结合具体实施方式说明本发明:但是可以理解这些具体的实施方式只是用于说明本发明,而不是对本发明的限制。本领域的技术人员完全可以在本发明的启示下,对本发明的的具体实施方式或者技术特征进行改进,但这些经过改进或替换的技术方案,仍属于本发明的保护范围。
实施例一
一、实验材料
主要仪器设备
电热恒温培养箱HZ-100(一恒科学仪器有限公司,中国上海);三孔电热恒温水槽DK-8D(一恒科学仪器有限公司,中国上海);海尔BCD-579WE冰箱(海尔,中国上海);CO2 恒温培养箱Forma 371(Thermo公司,美国);超净工作台SW-CJ-2FD(苏州安泰空气技术有限公司,中国江苏);生物安全柜1300SERIES A2(Thermo公司,美国);倒置光学显微镜(Nikon公司,日本);高速离心机Centrifuge 5804R(Eppendorf公司,德国);移液器Research plus(Eppendorf公司,德国);PCR仪C1000 Touch(Bio-Rad公司,美国);电泳仪PowerPac Basic(Bio-Rad公司,美国);垂直电泳槽MiniProtean Tetra (Bio-Rad公司,美国);凝胶成像系统2500(R)(Tanon公司,中国上海);超纯水仪 Milli-Q(Millipore公司,美国);超低温冰箱Forma 994(Thermo公司,美国);核酸蛋白分析仪Nano Drop 2000(Thermo公司,美国);生化培养箱LRH-250(一恒科学仪器有限公司,中国上海);分析天平BSA224S(Sartorius公司,德国);涡旋振荡器(Thermo 公司,美国)等。
主要试剂和材料
TIAN prep Mini Plasmid Kit(DP103-03)购自天根生化科技(北京)有限公司;Gel Extraction Kit(D2500-02)购自OMEGA;M-MLVRT(2641A)购自TAKARA;RRI(2313A) 购自TAKARA;Agarose(E0301)购自TSINGK;0.25%Trypsin-EDTA(25200-056),DMEM basic(C11995500BT)购自Gibco;Lipofectamine LTX and Plus Reagent(15338-100)购自Invitrogen;FBS(10099-141C)购自Gibco;Premix-Taq(RR902A)购自TAKARA;Pen Streppenicillin Streptomycin(15140-122)购自Gibco;Prime STAR GXL(R050)购自TAKARA;BtgZ1(R0703S),高浓度T4 DNA Ligase(M0202M)购自NEB;T4连接酶及其他常用限制性内切酶均购自TAKARA;ClonExpress Multis One Step Cloning Kit(C113) 购自南京诺维赞生物制品有限公司;Trizol 15596-026购自Invitrogen;氯仿,异丙醇,无水乙醇等生化试剂购自宁波萃英化学技术有限公司。
二、试验过程
1.构建带F基因突变的质粒pBR322-mFDHN3
为了将DHN3 F基因编码区的第112~117位氨基酸由强毒的“R-R-Q-K-R-F”突变成弱毒的“G-R-Q-G-R-L”序列。我们将DHN3 F基因与第112~117位氨基酸对应的碱基序列由“AGGAGACAAAAACGCTTT”突变为“GGGAGACAGGGGCGCCTT”后者与La Sota株F基因112-117位氨基酸的碱基序列相同。
具体实施如下:
首先用SmaI酶切质粒pBR322-DHN3(质粒pBR322-DHN3的制备可参考CN201910894754.9,一种针对II类VII型流行NDV株DHN3的感染性重组克隆方法中说明书第182段至208段,3.1.4构建全基因组表达载体pBR322-DHN3),通过0.8%琼脂糖凝胶电泳回收目的片段(13399bp)待用。酶切方法按说明书进行。
用两对引物change-F1-F/change-F1-R和change-F2-F/change-F2-R以pBR322-DHN3为模板扩增目的片段。引物中包含突变的F碱基序列和与SmaI酶切质粒同源的同源序列,两对PCR产物互含有同源臂(详见下面序列表)。第一对引物的PCR产物为3190bp;第二对引物的PCR产物为3106bp;。
表1构建质粒pBR322-mFDHN3的引物序列
注:斜体序列为酶切位点,加粗序列为同源序列,当酶切位点同为同源序列时斜体加粗
将PCR产物纯化后与SmaI酶切后的质粒在重组酶的作用下同源重组,获得含mF的质粒pBR322-mFDHN3。pBR322-mFDHN3质粒构造见下图2。同源重组反应方法按说明书进行。
2.拯救rDHN-mF重组病毒
将BHK-21细胞培养于6孔板中,次日细胞长至80%左右满。转染前30min,用PBS 清洗细胞3次,最后一次弃除PBS后每孔加入1ml Opti-MEM,将6孔板放回37℃5%CO2 培养箱中继续培养。同时用赛默飞Lipofectamine LTX DNA Transfection Reagents转染试剂按照试剂说明配制如下转染液:
A液:Opti-MEM Medium 150μl,Lipofectamine LTX Reagent 15μl,静置5min;
B液:Opti-MEM DNA 175μl其中pBR322-mFDHN3 4μg,pXJ40-NP 2.5μg,pXJ40-P1.25μg,pXJ40-L 1.25μg,pXJ40-DE3 3μg,PLUS Reagent 3.5μl,吹打混匀,静置5min。
pXJ40-NP,pXJ40-P、pXJ40-L、pXJ40-DE3的制备可参考CN 201910894754.9,一种针对II类VII型流行NDV株DHN3的感染性重组克隆方法中说明书108-153段。
取A液,B液各150μl混合均匀,静置20min。
取250μl混合液加入细胞培养液中,轻轻混匀,置37℃5%CO2培养。8h后弃除培养液,用PBS清洗3次后加含5%SPF鸡胚尿囊液和0.1%胰酶的DMEM培养液继续置37℃ 5%CO2培养。4天后收获细胞置-80度冻存。
3.rDHN3-mF重组病毒含正确的突变序列
将上述冻存细胞反复冻融2次后置4度离心10分钟。取上清病毒(rDHN3-mF)液感染BHK-21细胞。于此同时用DHN3病毒感染BHK-21细胞作为阳性对照,未接受感染的细胞为阴性对照。参考图3,其结果显示感染24h后被DHN3感染的细胞已出现大片死亡,同时受rDHN3-mF感染的细胞也出现大量死亡。阴性对照组细胞则无明显变化。图3左上示感染rDHN3-mF的BHK-21细胞,感染液为含0.1%trypsin的DMEM;右上为同为感染 rDHN3-mF的BHK-21细胞,感染液为含5%尿囊液的DMEM。左下示感染野生型DHN3的阳性对照;右下示未感染的阴性对照。
将上述rDHN3-mF感染的细胞置-80度冻存。经反复冻融2次后置4度离心10分钟。取上清病毒(rDHN3-mF)液并通过Trizol提取病毒RNA。用随机引物作反转录,用F基因特异型引物(C-PD2-F:GTCTCCTACTTGACAAGGTTATCGG;C-PD2-R: GACTCCATTCGCAAGATCCAAGGGTC)扩增F基因片段(1447bp)。
将PCR产物纯化后送生物工程公司测序。以上实验重复三次,RT-PCR结果均显示该PCR片段序列与设计的突变序列相同(如下图4所示),证明rDHN3-mF病毒RNA含突变的mF基因。
4.rDHN3-mF病毒在BHK-21细胞有很好的复制能力
为了确认突变病毒株rDHN3-mF的病毒复制能力我们分别测定了它与原毒DHN3以及重组病毒rDHN3在BHK-21细胞中的复制曲线。具体操作如下:
将BHK-21细胞培养于35mm培养皿,待细胞长至80~90%满时弃去培养液,用PBS清洗细胞三次。弃去PBS后每孔分别加入1ml含1MOI的病毒液,置培养箱孵育2h后弃去病毒液,用PBS再清洗三次。弃去PBS后加入2mlDMEM,受rDHM3-mF感染的细胞则加入2ml含0.01%胰酶的DMEM,置培养箱继续孵育。于感染后4h、8h、16h、24h、36h、 48h、60h分别将感染细胞置-80度冻存。将上述样品反复冻融2次后转入无菌离心管,置4度高速(rpm12000)离心10分钟,收获上清病毒液。分别测定以上各病毒液样本的 TCID50值,确定其病毒含量并绘制生长曲线。结果如图5-7所示,rDHN3-mF在BHK-21细胞中的复制曲线走势与原毒DHN3以及原毒重组病毒rDHN3非常相似。但rDHN3-mF病毒感染后在各时间点的TCID50值均略高于原毒株。这可能是由于感染rDHN3-mF时感染液中加了0.01%胰酶的缘故。胰酶可以协助F0裂解加速病毒入侵,但不影响复制。从感染4h时的TCID50值可以看出,此时感染rDHN3-mF的细胞中的病毒量已高于其余两株,而感染 4h时病毒尚未完成一个复制周期,这时的病毒多来自入侵的病毒。
总而言之上述结果证明rDHN3-mF病毒的复制能力不低于原毒DHN3和原毒重组病毒 rDHN3的复制能力。
TCID50测定方法
提前一晚将BHK-21细胞铺于96孔板中,待细胞长至80%~90%满后开始下一步实验。弃去培养皿中的培养液,用PBS清洗两次。将待检病毒液使用DMEM倍比稀释,稀释度为10-1~10-11。每孔分别加100μl上述稀释液,每个稀释度平行作三个孔。4~6天后观察病变,使用Reed-Muench法计算结果。为尽量减少误差,每个病毒样品测三次。
5.rDHN3-mF重组病毒毒力大大低于原毒株
1)测定尿囊液病毒TCID50
将原毒株DHN3,重组株rDHN3和突变株rDHN3-mF分别在SPF鸡胚中扩繁10代,收获第十代鸡胚尿囊液备用。分别测定各尿囊液的TCID50(细胞半致死量)。结果见下面图表,3株病毒尿囊液中病毒含量基本相同,TCID50均在108左右。
毒力测试如下表2
表2:毒力测试结果
病毒 | TCID50/ml | EID50/ml | MDT(h) |
DHN3 | 10<sup>8.26</sup> | 10<sup>7.63</sup> | 48 |
rDHN3 | 10<sup>8.98</sup> | 10<sup>7.5</sup> | 48 |
rDHN3-mF | 10<sup>8.47</sup> | 10<sup>8.68</sup> | 110.4 |
2)测定病毒的EID50(胚胎半致死量)
取新鲜健康的9~11日龄SPF鸡胚用于实验。用生理盐水将上述尿囊液作倍比稀释,稀释度为10-1~10-10。选取10-5~10-10稀释度进行实验,每个稀释度接种5枚SPF鸡胚,每枚接种100μl病毒液。每日照胚三次,弃去24h内死胚,连续观察6~7d。使用Reed-Muench 法计算鸡胚半数致死量。其结果显示rDHN3-mF毒株尿囊液EID50比原毒DHN3高近10倍,说明rDHN-mF的毒性较原毒DHN3低近10倍。rDHN3与DHN3毒株则几乎没有差异(详见上表)。
3)测定MDT(鸡胚平均致死时间)
取新鲜健康9-11日龄SPF鸡胚用于实验。用生理盐水将上述待检病毒尿囊液倍比稀释,稀释度为10-1~10-10。取10-5~10-10稀释度用于实验,每个稀释度接种5枚SPF鸡胚,每枚接种100μl病毒液。每日照胚三次,弃去24h内死胚,连续观察6~7d。使用Reed-Muench 法计算鸡胚平均致死时间。结果显示,DHN3与rDHN3毒的鸡胚平均致死时间均在48h而接种rDHN3-mF毒的鸡胚平均致死时间则为110.4h,比接种DHN3或rDHN3的鸡胚平均致死时间延长62.4h。
4)红细胞凝集(HA)实验检测感染鸡胚尿囊液中的病毒效价
取洁净96孔板,用排枪将每孔加入25μl生理盐水。取待检鸡胚尿囊液25μl加到第1孔中,吹打混匀。再从第1孔中取25μl加入第二孔中吹打混匀,再从第2孔中取出25μl加入第3孔中吹打混匀,按此作对倍稀释。弃去第11空中的25μl混匀液。每孔加1%鸡新鲜红细胞。20分钟后观察血凝结果。为减少实验误差,每个病毒样品测三次。结果发现,感染rDHN3-mF的鸡胚尿囊液显示了最高的HA效价,其值为29而感染DHN3 和rDHN3的鸡胚尿囊液中的HA效价均为28。
5)鉴定病毒感染后的器官病变
取一周龄SPF雏鸡分5组,每组12只,分别饲养于隔离器中养殖。分别用上述DHN3,rDHN3,rDHN3-mF尿囊液以及La Sota病毒尿囊液以106EID50剂量经点眼滴鼻途径接种各组雏鸡。阴性对照组(NC)雏鸡用生理盐水点眼滴鼻。接毒后观察各组动物的临床表现和死亡情况,共观察21天。
接毒后分别在第3天和第7天满时取各组鸡3只,分别进行剖检观察。重点观察肝脏,脾脏,气管,腺胃和十二指肠等器官的病理变化。攻毒后7,14,21天分别采各组动物的血清,通过HI试验测试血清中的抗体效价。
结果显示接毒2天后强毒组(DHN3、rDHN3)雏鸡均出现嗜睡,精神萎靡,排黄绿色稀粪等症状,并开始出现死亡,至第4天鸡只全部死亡。接毒后第三天每组剖检3只,强毒组示肝肾肿大出血、胸腺出血、部分可见脑部点状出血;接rDHN3-mF或La Sota的鸡只以及生理盐水对照组鸡群均表现出精神良好、羽毛柔顺、食欲旺盛。接毒后第7天,剖检见La Sota组有个别雏鸡脑组织示点状出血,心脏肿大出血,而rDHN3-mF组和生理盐水对照组(Control)组均未见明显出血和损伤。如图8和9所示:
6)检测血清特异型抗病毒抗体
接毒后7d,14d,21d分别从rDHN3-mF组,La Sota组以及生理盐水对照组雏鸡采血制备血清。分别使用DHN3和La Sota病毒作为抗原用红细胞凝集抑制(HI)方法检测上述血清中的抗病毒抗体效价。结果显示攻毒后21天雏鸡的血清rDHN3-mF组抗基因Ⅶ型 DHN3的抗体效价约为27,抗La Sota的抗体效价约为24.33;而攻La Sota毒后21天雏鸡的血清组抗基因Ⅶ型DHN3的效价则约为25.67,抗La Sota的效价约为25.33。总的说来接毒鸡群体内的特异性抗病毒抗体含量随时间增长而提高。详细结果如下表3所示:
表3:HI检测抗体效价
6.重组病毒rDHN3-mF的攻毒保护实验
1)制备rDHN3-mF灭活疫苗
将甲醛溶液适量加入上述rDHN3-mF感染鸡的尿囊液中,使其终浓度为0.05%,混合均匀。37℃灭活24h。期间每8h震荡混匀一次。灭活后的病毒液置-80℃保存。
取上述灭活病毒液,接种9日龄SPF鸡胚,每枚0.2ml,共接5个胚。置37℃培养箱中培养。弃去24h内的死胚。72h后收集所有鸡胚的尿囊液,通过HA方法检测所有尿囊液。结果显示无红细胞凝集,证明灭活完全,无活病毒残存。进一步在百级层流罩下完成下面操作:按照下面公式配制灭活苗:油(94%白油+6%司本80)/水(96%抗原+4%吐温 80)=3:2。其中油相混合后需高压灭菌。将水相缓慢加入油相,1000rpm/min,混匀10min。
2)接种上述rDHN3-mF灭活疫苗观察其对DHN3攻毒的保护性
选取一周龄的SPF雏鸡,分为rDHN3-mF灭活疫苗组,La Sota灭活疫苗组和生理盐水对照组,共3组,每组10只。将雏鸡分别饲养于隔离器中。用上述rDHN3-mF灭活疫苗和购买的商品化La Sota灭活疫苗以107EID50于每只雏鸡颈部作皮下注射,每只注射0.2ml, 对照组颈部皮下注射等体积生理盐水。免疫后7d,14d,21d于每组雏鸡作翅下静脉采血,每组随机采血5只制备血清作抗DHN3和抗La Sota病毒的特异性抗体检测。免疫三周后用强毒株DHN3以105EID50通过点眼滴鼻方式对各组进行攻毒感染。攻毒后观察10天,记录各组雏鸡的临床症状和死亡情况。与此同时在攻毒后3d,5d和7d分别采集各组雏鸡的喉头拭子和泄殖腔拭子。通过接种9~11日龄SPF鸡胚观察其病毒繁殖情况。每个拭子接种3枚鸡胚,孵育48h后收获尿囊液,作HA检测,3枚鸡胚中只要有一枚检测阳性,则该拭子确定为带毒。
结果如下表4显示,接种疫苗后无论针对DHN3病毒还是针对La Sota病毒的抗病毒抗体均随接种时间增长而增加,而接种生理盐水则不能刺激抗体产生。说明接种DHN3-mF和La Sota灭活疫苗均能产生良好的抗体。从接种14天起rDHN3-mF组显示出明显比La Sota组更高的抗DHN3抗体,其幅度增加了近1倍。而抗La Sota抗体,rDHN3-mF组和La Sota 组的抗体强度则无显著差异。两组产生的抗La Sota抗体均比rDHN3-mF组产生的抗DHN3 少1-2个滴度。说明DHN3-mF病毒的抗原性较La Sota病毒的抗原性强。这个结果与前面 HA检测病毒尿囊液的结果相符。
表4:免疫血清HI实验
排毒检测
将每个拭子用100μl生理盐水充分振荡后用0.4μm滤器过滤。在滤液中加入青链霉素使其终浓度为1%,然后将滤液接种在9~11日龄SPF。下表出示排毒检测的实验结果。rDHN3-mF免疫组在攻毒3d后10只鸡检测到9只喉头有排毒,但泄殖腔均未检测到排毒。攻毒后5d,7d的喉头和泄殖腔均未测到排毒。而La Sota免疫组攻毒3d,5d,7d的喉头拭子均检测到一定量的排毒。对照组鸡群在攻毒后3d,5d无论喉头还是泄殖腔均检测到100%的排毒。攻毒第7d因对照组鸡群全部死亡故无测试。
表5:不同疫苗免疫攻毒后排毒情况
从免疫动物的外观表现来看无论rDHN-mF组还是La Sota组用105EID50 DHN3攻毒后雏鸡在10天观察期内均表现正常。而生理盐水组攻毒后雏鸡开始出现嗜睡,食欲不振,精神萎靡,排黄绿色稀粪等症状,4天后开始出现死亡,至第7天鸡只全部死亡。
结论
将DHN3的F基因对应第112~117位氨基酸的碱基序列由“AGGAGACAAAAACGCTTT”突变为“GGGAGACAGGGGCGCCTT”不改变病毒的复制能力但显降低了原毒株的毒性。一般认为MDT<60h为强毒株,61h<MDT>90h为中等毒力毒株,MDT>91h为弱毒株。按此分类DHN3和rDHN3均为强毒株而rDHN3-mF毒株则属弱毒的范畴。
rDHN-mF是一株重组弱毒疫苗。灭活的rDHN-mF疫苗能有效保护VII型NDV感染并显示出比La Sota灭活疫苗更好的保护能力。
序列表
<110> 华农(肇庆)生物产业技术研究院有限公司
<120> 一种NDVVIId突变型感染性克隆病毒DHN3-mF及其制备方法和疫苗
<160> 6
<170> SIPOSequenceListing 1.0
<210> 1
<211> 15192
<212> DNA
<213> 人工序列()
<400> 1
accaaacaga gaatccgtga ggtacgataa aaggcgaaga agcaatcgag atcgtacggg 60
tagaaggtgt gaaccccgaa cgcgagatcg aagcttgaac ctgagggaac cttctaccga 120
tatgtcgtct gtttttgacg aatacgagca gctccttgct gcccagaccc gccctaacgg 180
agcccatgga gggggagaga aagggagcac cttaaaagtt gaggtcccag tatttaccct 240
aaacagtgat gatccagagg atagatggaa ctttgcggta ttctgtcttc ggattgccgt 300
tagtgaggat gccaacaaac cactcaggca aggtgctctt atatccctct tatgctccca 360
ttctcaggtg atgagaaacc atgttgccct tgcaggaaaa cagaacgagg ccacactagc 420
tgttcttgag atcgatggtt ttgctaataa tgtgccccag ttcaacaata ggagtggagt 480
gtccgaggag agagcacaga gattcatggt aattgcaggg tctctccctc gggcatgcag 540
caacggtact ccgtttgtca cggctggggt tgaagatgat gcaccagaag atatcactga 600
cactctggaa aggatcctat ctgtccaagt ccaagtatgg gtcacggtag caaaggccat 660
gactgcatat gagacagcag atgagtcaga aacaagaaga ataaataagt atatgcagca 720
gggtagagtc cagaagaagt acatccttca tcctgtatgc aggagtgcaa ttcaactcat 780
aatcagacat tctctggcag tccgtatttt cctggttagt gagctcaaga ggggccgtaa 840
tacagcaggt gggagctcta catattacaa tttggtcggg gatgtagact catacatcag 900
aaataccggg cttactgcgt ttttcctaac actcaaatat ggaatcaata ccaagacgtc 960
agctctcgca ctcagcagcc tcacaggtga tatccaaaaa atgaaacagc tcatgcgttt 1020
atatcggatg aaaggtgaaa atgcaccata catgacattg ttaggtgaca gtgaccagat 1080
gagctttgcg ccagccgaat atgcacaact ttattctttt gccatgggca tggcatcagt 1140
cttagataag ggaactggca agtaccaatt tgccagggac tttatgagca catcattctg 1200
gcgacttgga gtagagtatg ctcaggctca gggaagtagt atcaatgaag acatggctgc 1260
tgagttaaaa ctaaccccag cagcaaggag aggcctggca gctgctgccc aacgagtatc 1320
tgaagaaatc ggcagcatgg acattcctac tcaacaagca ggagtcctca ccgggctcag 1380
tgacgaaggc ccccgaactc cacagggtgg atcgaacaag ccgcaagggc aaccagatgc 1440
tggggatggg gagacccaat tcctggattt tatgagaaca gtggcgaaca gcatgcggga 1500
atcgcctaat cctgcacaga gcaccactca tctagagcct cccccgaccc ctggggcatc 1560
ccaagacaac gacactgact gggggtactg atcgactact cccagcctgc ctccatagga 1620
ccacaccaaa cccctccccc aaaacccccc cacacccccc gacccacaac cccgcacgac 1680
ccccccaaca aaagctcccc cccaccctct cccccacccc cagccacacg accccatcca 1740
cccgggacaa cacaggcaca gctcggccag tcaacaatcc tcccagagtc caaggtatta 1800
gaaaaaaata cgggtagaag agagacatcc agagaccagg acgggtcacc aagctctctg 1860
ttctcccttc tacccggtga gttagggtga agatggctac ctttacagat gcggagatag 1920
atgacatact tgagaccagt gggactgtca ttgatagcat aattacggcc cagggcaaat 1980
cagccgagac cgtcggaaga agtgcgatcc cgcagggcaa gaccaaagct ccaagcacag 2040
cacgggagaa gcacgggagt gcccagccac acgccagtca ggacgtcccc gaccaacaag 2100
acagaacaga aaaacagcca tccacacctg agcaggcaac cccacacaac aacccaccga 2160
ccacacccac cgaaccgccc tccacccagg ccgcaagcga gaccagcgac acacagctca 2220
aaaccggagc aagcaactcc cttctgtcca tgctcgacaa attaagcaat aaatcgtcta 2280
atgctaaaaa gggcccatgg tcgggtcccc aagaagggca tcaccaatct ccggcccaac 2340
aacacgggaa ccagtcgagc catggaagca accagggaag accacagcac caggtcaagg 2400
ccgtctctgg aaaccggggc atagacgaga acacagcata tcatggacaa cggaaggagt 2460
cacaaccatc agctggtgca acccctcatg cgccccagtc agggcagagc caagacaata 2520
ttcctgtacc tgtggatcgt gtccagctac ctgccgactt tgcgcaggcg atgatgtcta 2580
tgatggaggc attatctcag aaggtaagta aagttgatca tcagctggat ctggtcttga 2640
aacagacatc ctctattcct atgatacgat ctgaaatcca acagctcaag acatctgttg 2700
cgatcatgga agctaactta ggtatgatga aaattctgga ccctggttgt gccaacattt 2760
catctttaag tgatctccgg gcagtagccc gatcccaccc agtcctagtt tcgggccccg 2820
gagacccatc tccttacgtg acacaagagg gtgaaatgac gctcaataaa ctctcacaac 2880
cagtgcagca cccttctgaa ttgattaagt ctgccaccgc aagcgggcct gacatgggag 2940
tggagaagga cactgtccgc gcattaatca cctcacgccc gatgcatcca agctcctcgg 3000
ctaagctcct gagcaagcta gatgcagcca agtcaattga agagatcagg aagatcaagc 3060
gccttgcgct gaatggttga tggccgtcac aactcatagc aggctcctgt cgcttcagca 3120
tcacacggaa tcccccggga gccccccctt gcgaatccat gcttcaacac cccagacaac 3180
agccctctct caccatcccc aatccctcgc atgatcgcac aactgcaacc aatctagcag 3240
cattagagat taagaaaaaa cacgggtaga atcaaagtgc ctcgattgaa ccaaaatgga 3300
ctcatccagg acaatcgggc tgtactttga ttctgccctt ccttccagta gcctattagc 3360
atttccgatt atcttacaag atacaggaga cgggaagaaa caaatcactc cacaatacag 3420
gatccagcat cttgattcgt ggacagacag taaggaagac tcggtattta tcaccaccta 3480
cgggttcatc tttcaagttg ggaatgaagg agccactgtc ggtgtgatca atgacaatcc 3540
caggcatgag ctactctctt ccgcaatgct ctgcttaggg agtgtcccga acaacggaga 3600
tcttgttgag ctggcgagag cctgcctcac tatggtggta acctgcaaga agagtgcaac 3660
taacactgag agaatagtct tctcagtagt gcaggcacct cgagtgctgc aaaattgtat 3720
ggttgtgtca aatcggtact catcagtgaa tgcagtgaag catgtgaagg cgcccgaaaa 3780
gatccctggg agcggaaccc tagagtataa agtgaatttt gtctccttga ctgtggtgcc 3840
gagaagggat gtctacagga tcccaactac agtattgaaa gtgtctggct cgagcctgta 3900
caatcttgcg ctcaatgtca ctattgatgt ggacgtggat ccgaagagcc cgttagtcaa 3960
atccctttct aagtccgata gcgggtacta tgcgaatctt tttctgcata tcggacttat 4020
gtccactgta gataagagag gaaagaaagt gacatttgac aagatagagg aaaagataag 4080
gagactcaat ctatctgttg ggctcagtga tgtgctcgga ccctctgtgc ttgtgaaggc 4140
gagaggtgca cggactaagc tacttgctcc tttcttctct agcagtggga cagcctgcta 4200
tcctatagca aatgcctctc cccaggttgc caagatactc tggagccaga ccgcgcacct 4260
gcggagcgtg aaagtcatca ttcaagccgg cactcagcgt gctgttgcag tgaccgccga 4320
tcatgaggta acctccacta agatagagaa gaagcatgcc attgctaaat acaatccttt 4380
cagaaaatag gttacatccc taagactgca gttcacctgc tttcccgaat catcatgaca 4440
ccagataatg atccatctcg actgcttgta gttagttcac ctgtccagca aattagaaaa 4500
aacacgggta gaagagtctg gaccccgacc ggcacactca ggacacagca tgggctccaa 4560
accttctacc aggatcccag cacctctaat gctaatcact cgaattatgc tgatattgaa 4620
ctgcatccgt ctgacaagtt ctcttgacgg caggcccctt gcagctgcag gaattgtaat 4680
aacaggagat aaggcagtca atgtatatac ctcgtctcag acagggtcaa tcatagtcaa 4740
gttgctcccg aatatgccca gagataagga ggcatgtgca agagccccat tggaggcata 4800
taacagaaca ctgactactc tgctcactcc tcttggcgac tccattcgca agatccaagg 4860
gtctgtatcc acgtccggag gagggagaca ggggcgcctt ataggtgctg ttattggcag 4920
tgtagctctc ggggttgcaa cagcggcaca gataacagca gctgcggccc taatacaagc 4980
caaacagaat gctgccaaca tcctccggct taaggagagc attgctgcga ccaatgaagc 5040
tgtgcatgaa gtcaccgacg gattatcaca attatcagtg gcagttggga agatgcaaca 5100
gtttgtcaat gaccagttta ataacacggc gcgagaatta gactgcataa aaatcacaca 5160
acaggtcggt gtagaactca acctatacct aactgagcta actacagtat tcgggccaca 5220
gatcacctcc cctgcattaa ctcagctaac catccaggcg ctctataatt tagctggtgg 5280
caatatggac tacttattaa ctaagttagg tataggaaac aatcaactca gctcattaat 5340
tggtagcggc ctgatcactg gttaccctat actgtatgac tcacatactc aactcttggg 5400
catacaagtt aatctgccct cagtcgggaa cttaaataat atgcgtgcca cctatctgga 5460
gaccttatct gtaagtacaa ccaaaggata tgcctcagca ctggtcccga aagtagtgac 5520
acaagtcggt tctgtgatag aagagcttga cacctcatac tgtatagagt ccgatctgga 5580
tttatattgt actagaatag tgacattccc catgtctcca ggtatttatt cctgtttaag 5640
tggcaacaca tcagcctgca tgtattcaaa gactgaaggc gcactcacta cgccgtatat 5700
ggcccttagg ggctcagtta ttgctaattg taagataaca acatgcagat gtacagaccc 5760
tcctggcatc atatcgcaaa attatggaga agctgtatcc ctgatagata gacactcgtg 5820
caatgtctta tcattagacg gcataactct gaggctcagt ggggaatttg atgcaactta 5880
tcaaaagaac atctcaatat tagattctca ggtcatcgtg acaggcaatc ttgatatatc 5940
aactgaactt ggaaacgtca ataattcgat cagcaatgcc ttggacaagt tggcagaaag 6000
caacagcaaa ctagaaaaag tcaacgtcag actaactagc acatccgctc tcattaccta 6060
tattgttcta actgtcattt ccctaatttt cggtgcactt agtctggttt tagcgtgtta 6120
cctgatgtac aagcagaagg cacaacaaaa gaccctgtta tggcttggga acaataccct 6180
cgatcagatg agagccacca tgagagcatg aatgcaaata ggaagtggac ggacacccaa 6240
cggcagcccg tgtgtcaatt ccgataacct gtcaagtagg agacttaaga aaaaattact 6300
gggaacaagc aaccaaagag caatacacgg gtagaacggt cagaggagcc acccttcaat 6360
tgaaaattag gcttcacaac atccgttcta ccacaccacc aacaacaaga gtcaatcatg 6420
gaccgcgtgg ttaacagagt catgctggag aatgaagaaa gagaagcaaa gaacacatgg 6480
cgcttagttt tccggatcgc agtcttattt ttaatggtaa tgattctagc tatctctgcg 6540
gctgccctgg catacagcat ggaggccagt acgccacacg acctcgcagg catatcgact 6600
gtgatctcca agacagaaga taaggttacg tctttactca gttcaagcca agatgtgata 6660
gataagatat acaagcaggt agctcttgaa tccccgctgg cactattaaa caccgaatct 6720
gtaattatga atgcaataac ctctctttct tatcaaatta acggggctga gaacagtagc 6780
ggatgcggtg cgcccgttca tgacccagat tatatcgggg ggataggcaa agaactcata 6840
gtggacgaca ttagtaatgt cgcatcattt tatccttctg catatcaaga acacttgaat 6900
ttcatcccgg cacctactac aggatctggt tgcactcgga taccctcatt tgacatgggc 6960
accacccatt attgttatac tcacaatgtg atactatctg gttgcagaga tcactcacac 7020
tcacatcaat acctagcact tggtgtgctt cggacatctg caacagggag ggtattcttt 7080
tctactctgc gctccatcaa tttagatgac actcaaaatc ggaagtcttg cagtgtgagt 7140
gcaacccctt taggttgtga tatgctgtgc tctaaggtca cagggactga agaggaggat 7200
tacaagtcag ttgcccccac atcaatggtg cacggaaggc taggatttga cggtcaatac 7260
catgagaaag acttagacac cacggtctta tttaaggatt gggtggcaaa ttacccgggg 7320
gtgggaggag ggtcttttat tgacggccgt gtatggttcc cagtttacgg agggctcaaa 7380
cctaattcac ccagtgacat cgcacaagaa gggaaatatg taatatacaa gcgccataat 7440
aacacatgcc ccgataaaca agattaccaa attcggatgg ctaagtcctc atataaacct 7500
gggcgatttg gtggaaagcg cgtacagcaa gctatcctat ctatcaaagt gtcaacatcc 7560
ctgggtaagg acccggtgct gactattcca cctaatacaa tcacactcat gggagccgaa 7620
ggcagaatcc tcacagtagg gacatctcac ttcttgtatc aacgagggtc ttcatatttc 7680
tcccctgcct tattgtatcc catgacagta agtaacaaaa cggctacact ccatagtcct 7740
tacatgttta atgctttcac tcggccaggt agtgtccctt gccaggcatc agcaaggtgc 7800
cccaactcat gcatcactgg ggtctatacc gatccatatc ccttaatctt ctataggaat 7860
catactctac gaggggtctt cgggacgatg cttgatgatg aacaagcgag gcttaacccc 7920
gtatctgcag tatttgacaa catatctcgc agtcgtgtca cccgggtgag ttcaagcaac 7980
accaaggcag catacacgac atcgacatgt tttaaagttg tcaagactaa taaagtttat 8040
tgtcttagta tcgcagaaat atccaatacc ctattcgggg aatttaggat cgttcccttg 8100
ctagttgaga tcctcaaaga tgatagagtt taagaagcta gacttggccg attgagccaa 8160
tcataggatg gttgggagga cgacattgcg ccaatcatct cccataatgc ttagagtcaa 8220
gctgaacatt agcataaatc aggatcccgt gttgttgggc aaccgcaatc cgacaatgct 8280
gacatgattg ttctgagtct cgctcactgt cactttatta agaaaaaaca caagaagcat 8340
tgacatataa gggaaaataa ccaacaagag agaacacggg taggacatgg cgggctccgg 8400
tcctgagagg gcagagcacc agatcatcct accagagtca catttatcct ctccattggt 8460
caagcacaaa ttgttatact actggaaatt aaccgggcta ccgcttcctg atgaatgcga 8520
ctttgatcat ctcattatca gcaggcaatg gaagagaata ctggagtcag ccactcctga 8580
cacagagaga atgataaaac ttgggcgggc ggtgcaccag actctcaacc acaattccaa 8640
gatgactgga gtgctccatc ccaggtgttt agaagaactg gctagtattg aggtccctga 8700
ttcaactaac aaattccgga agattgaaaa gaagatccag attcacaaca caagatatgg 8760
agacctgttc acaaagctgt gcgtgcaagt tgagaagaaa ttgctagggt catctctgtc 8820
taataatgtc ccacgatcag aggaattcaa cagcatccgt acagatccgg cattctggtt 8880
tcactcaaaa tggtccagag ccaagttcgc gtggctccat ataaaacaag tccaaaggca 8940
tctgattgta gcagcaagga caaggtctgc agtcaacaag ttagtaacat taaatcataa 9000
gataggccat gtctttatta ctcctgagct tgtcattgtg acacacacag acgagaacaa 9060
gttcacatgt ctcacccagg aacttgtatt gatgtatgcg gatatgatgg aaggcaggga 9120
catggtcaat ataatatctt ctacagcagc acatctcagg aacctatccg agaaaattga 9180
tgatattctg cggttagtag atgctctggc aaaggactta ggtaatcaag tctatgatgt 9240
tgtagcatta atggagggat ttgcatacgg tgccgttcag ctgcttgagc catcaggtac 9300
atttgcagga gatttctttg catttaacct acaggagctc aaaaacacgt taatcgaact 9360
tctccccaat aatatagcgg aagcagtaac tcacgctatt gccactgtat tctctggatt 9420
agaacagaac caagcagctg agatgttgtg cttgctgcgt ttgtggggtc atccattgct 9480
tgagtctcgt agtgcagcaa gagcagtcag gagccagatg tgcgcaccaa agatggtaga 9540
ctttgatatg atcctccagg tattatcttt ctttaaagga acaatcatca atggatacag 9600
aaaaaagaac tcaggtgtgt ggccacgcgt caaagtagat acaatatatg gaaatatcat 9660
tgggcagcta catgctgatt cagcagagat ctcacatgat gtcatgttga gggagtacaa 9720
gagtttatcc gctcttgaat ttgagccatg tatagattat gaccctgtta ccaatctaag 9780
catgttccta aaagacaagg caatcgcaca tcctagtgat aactggctcg cctcatttag 9840
gcggaaccta ctctctgagg accagaagaa acagataaag gaggcaactt caactaaccg 9900
cctcctgata gagttcttag aatcaaatga ttttgatcca tataaagaaa tggaatacct 9960
gacaaccctc gagtacctaa gagatgacag tgtggcagta tcgtactcac tcaaagagaa 10020
agaggtgaaa gtgaatggac ggatttttgc taaattaaca aagaaactaa ggaattgcca 10080
ggtaatggca gaaggaattc tagctgacca gattgcacct ttcttccagg gaaatggggt 10140
cattcaagat agcatatcct tgacaaagag tatgttagca atgagtcaac tgtcctttaa 10200
cagcaataag aaacgtatcg ctgactgcaa agagagggtt tcctcaaacc gcaatcatga 10260
tcccaagagc aagaatcgta gaagagttgc cacctttatc acgactgacc tacaaaagta 10320
ttgtcttaac tggagatatc agacagtcaa actattcgcc catgccatca atcagctgat 10380
gggcctacct catttctttg agtggattca tcttaggctg atggacacta caatgtttgt 10440
aggggatcct ttcaatcctc caagtgaccc gaccgactgt gatctatcaa gagtcccaaa 10500
tgatgatata tatattgtca gtgctagagg gggcattgag ggactctgtc agaagctatg 10560
gacgatgatc tcaattgctg caatccaact tgccgcagca agatctcatt gtcgagttgc 10620
ctgcatggta caaggtgaca atcaagtaat agctgtaacg agagaggtga gatcagatga 10680
ttccccggat atggtattga cgcagttgca tcaggctagt gataatttct tcaaggaatt 10740
gattcatgtc aatcatctga ttggccataa cctgaaggat cgtgaaacca ttagatcaga 10800
cacattcttc atatacagca aacgaatatt caaagatgga gcaatactca gtcaggtcct 10860
caaaaattca tctaaattgg tgctaatatc aggtgacctt agcgaaaaca ctgtaatgtc 10920
ctgtgccaac attgcatcca ctgtagcacg actatgtgag aatgggcttc ctaaggactt 10980
ctgttactat ttgaactacc taatgagttg cgtgcagaca tattttgatt cagagttttc 11040
tattactcac agctcacagt cagattccaa ccagtcctgg attgaggata tctctttcgt 11100
acactcatac gtgttaaccc ctgcccaact ggggggactg agtaaccttc aatactcaag 11160
gctctacaca aggaatattg gcgacccagg gaccactgcc tttgcagagg tcaagcgact 11220
agaagcagtg gggttgttga gtcccagcat catgactaac atcttaacca ggccacctgg 11280
caatggagat tgggccagcc tatgcaacga cccatactct tttaattttg agactgttgc 11340
aagcccaaat attgtcctca agaaacatac acagaaagtc ctatttgaga catgttcaaa 11400
ccctttatta tccggggtac atacagagga caatgaggca gaagagaaag cattggctga 11460
attcttactc aatcaagaag tgattcaccc acgtgtcgca catgctatca tggaagcaag 11520
ctctgtgggt aggagaaagc aaattcaagg gcttgttgac acaacgaaca ctgtgattaa 11580
gattgcactg actaggaggc ccctcggtat caaaagactg atgcggataa tcaattactc 11640
aagcatgcat gcaatgttgt tcagggatga tattttctta tccactagat ccaaccaccc 11700
attagtttct tctaatatgt gctcgctgac gctagcagat tatgctcgga acagaagctg 11760
gtcacccctg acagggggca ggaaaatact gggtgtatcc aaccccgata ccatagaact 11820
tgtggaggga gagattctca gcgtcagtgg agggtgcaca aaatgtgaca gcggagatga 11880
gcagtttact tggttccatc ttccaagcaa tatagagttg actgatgaca ccagcaaaaa 11940
tcccccgatg agagtgccat atctcgggtc gaagactcaa gagagaagag ccgcctcact 12000
tgcgaaaata gcccatatgt caccacatgt gaaagcagca ctaagggcat catccgtgtt 12060
aatctgggct tatggggaca atgaagtgaa ctggactgct gctcttaata ttgcaaggtc 12120
tcgatgcaac ataagctcag agtatcttcg gctattgtca cccctgccca cagctgggaa 12180
tctccaacat agattggatg atggcataac ccagatgaca tttacccctg catctctcta 12240
cagagtgtcg ccttacattc acatatccaa tgattctcaa aggctgttca ccgaagaagg 12300
ggtcaaagag ggaaacgtgg tttaccagca aattatgctc ttgggtttat ctctaattga 12360
gtcactcttc ccaatgacaa caaccagaac atacgatgag atcacattac acctccacag 12420
taaatttagc tgctgtatcc gagaagcgcc tgtcgcagtt cctttcgagc tcctcggact 12480
ggtaccggaa ttaaggatgg taacctcaaa taagttcatg tatgatccta gccctatatc 12540
agagagggat tttgcgagac ttgacttagc tatattcaag agttatgagc ttaacttgga 12600
atcatatccc acgctggagc taatgaacat tctttcgata tctagcggga aattgattgg 12660
ccaatctgtg gtttcttatg atgaagatac ttctataaag aatgatgcta taatagtgta 12720
tgacaacaca cggaattgga ttagtgaggc acagaactca gatgtggtcc gcctgtttga 12780
gtatgcagca ctcgaagtgc tcctcgactg tgcttatcaa ctctactatc tgagggtaag 12840
gggtctaaac aacatcgtcc tatacatgaa tgacttatat aagaacatgc cagggatcct 12900
actctccaat attgcagcca cgatatccca ccccctcatt cactcaaggt tgaatgcagt 12960
aggtctaatt aatcatgacg ggtcacacca gcttgcagat atagactttg tcgaggtgtc 13020
tgcgaaattg ttagtctcct gcactcgacg cgtggtctca ggtttatatg cagggagtaa 13080
gtatgatctg ctgtttccat ctgtcttaga tgataacctg aatgagaaga tgcttcaact 13140
aatttcccgg ttatgctgct tgtacacagt gctctttgct acaacaagag aaatcccaaa 13200
aataaggggc ctatcagcag aagagaaatg ctcaatactc actgagtatc tattgtcgga 13260
tgctgtaaaa ccgttgctta ggtccgaaca attgagttct atcatgtctc ccaacataat 13320
cacgttccca gccaatctat actacatgtc taggaagagc cttaatttga tcagagaacg 13380
agaggacaga gatactatct tgtcgttgtt gttccctcag gagtcactgc ttgagcttcg 13440
cccagtacgg gacattggtg ctcgagtgaa agacccgttt acccgacaac ccgcatcttt 13500
catacaagag ctggatctga gtgccccagc aaggtacgac gcgtttacac tgagtaagat 13560
ttgcttcgag cacacactac cgaacccaag ggaagattac ctagtacgat acttgttcag 13620
aggagtaggg actgcttcat cttcttggta taaggcgtct catcttctat ccatatctga 13680
ggttaggtgt gcaagacatg ggaactcttt atacttagcg gaaggaagcg gagccatcat 13740
gagtcttctt gaattgcata taccacatga gaccatctat tacaatacac ttttctcgaa 13800
tgagatgaac cctccacagc ggcatttcgg acctacacca acacagtttc taaactcggt 13860
cgtttatagg aatctacaag cggaagtgcc atgtaaagat ggatatgtcc aggagttcta 13920
tccattatgg agagagaatg cagaagaaag tgatctgacc tcagataagg cagttggata 13980
tatcacatct gtagtaccct acaggtctgt atcattacta cattgtgaca ttgagattcc 14040
tccagggtcc agtcaaagct tattagatca actggctact aatttatccc tgattgccat 14100
gcattctgtg agagagggcg gggtagtgat catcaaggta ctgtatgcaa tggggtacta 14160
cttccactta ctcatgaatt tattcactcc atgttccacg aaaggataca tactttccaa 14220
tggctacgcc tgtagagggg atatggagtg ttacctgata ttcgttatgg gctgcttagg 14280
cgggcccact ttcgtgcacg aagtggtaag gatggcaaaa gctctaatac aacgacacgg 14340
tacacttcta tctaaatcag atgaaatcac attgactaag ctatttacct cacagcagcg 14400
tcgtgtaaca gatctcctat ccagcccttt accgaagcta atgaggctct taagtgaaaa 14460
cattgatgct gcactaattg aagccggggg acagcccgtc cgtccatttt gtgcagaaag 14520
tttggtgagc acactaacaa atacgaccca gacaactctg atcattgcca gccacattga 14580
cacagtcatc cggtccgtga tttacatgga ggctgagggt gacctcgccg acacagtgtt 14640
cttattaact ccttacaatc tatccacaga cggtaaaaag agaacatcac ttaagcagtg 14700
caccaaacag atcttggaag tcacaatatt gggtctcaga gccaaagaca tcaataaaat 14760
aggtgatgta atcagcttag tactcagagg tgcgatttcc ctagaggacc tcatcccatt 14820
aaggacatac ctgaagcaca gtacctgtcc taaatacctg aaagcggtcc taggtattac 14880
taagctcaaa gaaatgttca caggtacttc gttattgtac ttgactcgcg ctcaacaaaa 14940
attctacatg aaaactatag gtaatgctgc caagggatat tacagtaata atgactctta 15000
aaggcaatcg tacaccaatc agttatcttc ttaactgatg actccctcat tgacttgatt 15060
ataccagatt agaaaaaagt taaattctga ctctttggaa ctcgtattcg gattcagtta 15120
gttaacttta agcaaaaatg cgcaaagtcg tctctaatca cagctatgtc attcaccaaa 15180
tctctgtttg gt 15192
<210> 2
<211> 15192
<212> DNA
<213> 人工序列()
<400> 2
accaaacaga gaatccgtga ggtacgataa aaggcgaaga agcaatcgag atcgtacggg 60
tagaaggtgt gaaccccgaa cgcgagatcg aagcttgaac ctgagggaac cttctaccga 120
tatgtcgtct gtttttgacg aatacgagca gctccttgct gcccagaccc gccctaacgg 180
agcccatgga gggggagaga aagggagcac cttaaaagtt gaggtcccag tatttaccct 240
aaacagtgat gatccagagg atagatggaa ctttgcggta ttctgtcttc ggattgccgt 300
tagtgaggat gccaacaaac cactcaggca aggtgctctt atatccctct tatgctccca 360
ttctcaggtg atgagaaacc atgttgccct tgcaggaaaa cagaacgagg ccacactagc 420
tgttcttgag atcgatggtt ttgctaataa tgtgccccag ttcaacaata ggagtggagt 480
gtccgaggag agagcacaga gattcatggt aattgcaggg tctctccctc gggcatgcag 540
caacggtact ccgtttgtca cggctggggt tgaagatgat gcaccagaag atatcactga 600
cactctggaa aggatcctat ctgtccaagt ccaagtatgg gtcacggtag caaaggccat 660
gactgcatat gagacagcag atgagtcaga aacaagaaga ataaataagt atatgcagca 720
gggtagagtc cagaagaagt acatccttca tcctgtatgc aggagtgcaa ttcaactcat 780
aatcagacat tctctggcag tccgtatttt cctggttagt gagctcaaga ggggccgtaa 840
tacagcaggt gggagctcta catattacaa tttggtcggg gatgtagact catacatcag 900
aaataccggg cttactgcgt ttttcctaac actcaaatat ggaatcaata ccaagacgtc 960
agctctcgca ctcagcagcc tcacaggtga tatccaaaaa atgaaacagc tcatgcgttt 1020
atatcggatg aaaggtgaaa atgcaccata catgacattg ttaggtgaca gtgaccagat 1080
gagctttgcg ccagccgaat atgcacaact ttattctttt gccatgggca tggcatcagt 1140
cttagataag ggaactggca agtaccaatt tgccagggac tttatgagca catcattctg 1200
gcgacttgga gtagagtatg ctcaggctca gggaagtagt atcaatgaag acatggctgc 1260
tgagttaaaa ctaaccccag cagcaaggag aggcctggca gctgctgccc aacgagtatc 1320
tgaagaaatc ggcagcatgg acattcctac tcaacaagca ggagtcctca ccgggctcag 1380
tgacgaaggc ccccgaactc cacagggtgg atcgaacaag ccgcaagggc aaccagatgc 1440
tggggatggg gagacccaat tcctggattt tatgagaaca gtggcgaaca gcatgcggga 1500
atcgcctaat cctgcacaga gcaccactca tctagagcct cccccgaccc ctggggcatc 1560
ccaagacaac gacactgact gggggtactg atcgactact cccagcctgc ctccatagga 1620
ccacaccaaa cccctccccc aaaacccccc cacacccccc gacccacaac cccgcacgac 1680
ccccccaaca aaagctcccc cccaccctct cccccacccc cagccacacg accccatcca 1740
cccgggacaa cacaggcaca gctcggccag tcaacaatcc tcccagagtc caaggtatta 1800
gaaaaaaata cgggtagaag agagacatcc agagaccagg acgggtcacc aagctctctg 1860
ttctcccttc tacccggtga gttagggtga agatggctac ctttacagat gcggagatag 1920
atgacatact tgagaccagt gggactgtca ttgatagcat aattacggcc cagggcaaat 1980
cagccgagac cgtcggaaga agtgcgatcc cgcagggcaa gaccaaagct ccaagcacag 2040
cacgggagaa gcacgggagt gcccagccac acgccagtca ggacgtcccc gaccaacaag 2100
acagaacaga aaaacagcca tccacacctg agcaggcaac cccacacaac aacccaccga 2160
ccacacccac cgaaccgccc tccacccagg ccgcaagcga gaccagcgac acacagctca 2220
aaaccggagc aagcaactcc cttctgtcca tgctcgacaa attaagcaat aaatcgtcta 2280
atgctaaaaa gggcccatgg tcgggtcccc aagaagggca tcaccaatct ccggcccaac 2340
aacacgggaa ccagtcgagc catggaagca accagggaag accacagcac caggtcaagg 2400
ccgtctctgg aaaccggggc atagacgaga acacagcata tcatggacaa cggaaggagt 2460
cacaaccatc agctggtgca acccctcatg cgccccagtc agggcagagc caagacaata 2520
ttcctgtacc tgtggatcgt gtccagctac ctgccgactt tgcgcaggcg atgatgtcta 2580
tgatggaggc attatctcag aaggtaagta aagttgatca tcagctggat ctggtcttga 2640
aacagacatc ctctattcct atgatacgat ctgaaatcca acagctcaag acatctgttg 2700
cgatcatgga agctaactta ggtatgatga aaattctgga ccctggttgt gccaacattt 2760
catctttaag tgatctccgg gcagtagccc gatcccaccc agtcctagtt tcgggccccg 2820
gagacccatc tccttacgtg acacaagagg gtgaaatgac gctcaataaa ctctcacaac 2880
cagtgcagca cccttctgaa ttgattaagt ctgccaccgc aagcgggcct gacatgggag 2940
tggagaagga cactgtccgc gcattaatca cctcacgccc gatgcatcca agctcctcgg 3000
ctaagctcct gagcaagcta gatgcagcca agtcaattga agagatcagg aagatcaagc 3060
gccttgcgct gaatggttga tggccgtcac aactcatagc aggctcctgt cgcttcagca 3120
tcacacggaa tcccccggga gccccccctt gcgaatccat gcttcaacac cccagacaac 3180
agccctctct caccatcccc aatccctcgc atgatcgcac aactgcaacc aatctagcag 3240
cattagagat taagaaaaaa cacgggtaga atcaaagtgc ctcgattgaa ccaaaatgga 3300
ctcatccagg acaatcgggc tgtactttga ttctgccctt ccttccagta gcctattagc 3360
atttccgatt atcttacaag atacaggaga cgggaagaaa caaatcactc cacaatacag 3420
gatccagcat cttgattcgt ggacagacag taaggaagac tcggtattta tcaccaccta 3480
cgggttcatc tttcaagttg ggaatgaagg agccactgtc ggtgtgatca atgacaatcc 3540
caggcatgag ctactctctt ccgcaatgct ctgcttaggg agtgtcccga acaacggaga 3600
tcttgttgag ctggcgagag cctgcctcac tatggtggta acctgcaaga agagtgcaac 3660
taacactgag agaatagtct tctcagtagt gcaggcacct cgagtgctgc aaaattgtat 3720
ggttgtgtca aatcggtact catcagtgaa tgcagtgaag catgtgaagg cgcccgaaaa 3780
gatccctggg agcggaaccc tagagtataa agtgaatttt gtctccttga ctgtggtgcc 3840
gagaagggat gtctacagga tcccaactac agtattgaaa gtgtctggct cgagcctgta 3900
caatcttgcg ctcaatgtca ctattgatgt ggacgtggat ccgaagagcc cgttagtcaa 3960
atccctttct aagtccgata gcgggtacta tgcgaatctt tttctgcata tcggacttat 4020
gtccactgta gataagagag gaaagaaagt gacatttgac aagatagagg aaaagataag 4080
gagactcaat ctatctgttg ggctcagtga tgtgctcgga ccctctgtgc ttgtgaaggc 4140
gagaggtgca cggactaagc tacttgctcc tttcttctct agcagtggga cagcctgcta 4200
tcctatagca aatgcctctc cccaggttgc caagatactc tggagccaga ccgcgcacct 4260
gcggagcgtg aaagtcatca ttcaagccgg cactcagcgt gctgttgcag tgaccgccga 4320
tcatgaggta acctccacta agatagagaa gaagcatgcc attgctaaat acaatccttt 4380
cagaaaatag gttacatccc taagactgca gttcacctgc tttcccgaat catcatgaca 4440
ccagataatg atccatctcg actgcttgta gttagttcac ctgtccagca aattagaaaa 4500
aacacgggta gaagagtctg gaccccgacc ggcacactca ggacacagca tgggctccaa 4560
accttctacc aggatcccag cacctctaat gctaatcact cgaattatgc tgatattgaa 4620
ctgcatccgt ctgacaagtt ctcttgacgg caggcccctt gcagctgcag gaattgtaat 4680
aacaggagat aaggcagtca atgtatatac ctcgtctcag acagggtcaa tcatagtcaa 4740
gttgctcccg aatatgccca gagataagga ggcatgtgca agagccccat tggaggcata 4800
taacagaaca ctgactactc tgctcactcc tcttggcgac tccattcgca agatccaagg 4860
gtctgtatcc acgtccggag gaaggagaca aaaacgcttt ataggtgctg ttattggcag 4920
tgtagctctc ggggttgcaa cagcggcaca gataacagca gctgcggccc taatacaagc 4980
caaacagaat gctgccaaca tcctccggct taaggagagc attgctgcga ccaatgaagc 5040
tgtgcatgaa gtcaccgacg gattatcaca attatcagtg gcagttggga agatgcaaca 5100
gtttgtcaat gaccagttta ataacacggc gcgagaatta gactgcataa aaatcacaca 5160
acaggtcggt gtagaactca acctatacct aactgagcta actacagtat tcgggccaca 5220
gatcacctcc cctgcattaa ctcagctaac catccaggcg ctctataatt tagctggtgg 5280
caatatggac tacttattaa ctaagttagg tataggaaac aatcaactca gctcattaat 5340
tggtagcggc ctgatcactg gttaccctat actgtatgac tcacatactc aactcttggg 5400
catacaagtt aatctgccct cagtcgggaa cttaaataat atgcgtgcca cctatctgga 5460
gaccttatct gtaagtacaa ccaaaggata tgcctcagca ctggtcccga aagtagtgac 5520
acaagtcggt tctgtgatag aagagcttga cacctcatac tgtatagagt ccgatctgga 5580
tttatattgt actagaatag tgacattccc catgtctcca ggtatttatt cctgtttaag 5640
tggcaacaca tcagcctgca tgtattcaaa gactgaaggc gcactcacta cgccgtatat 5700
ggcccttagg ggctcagtta ttgctaattg taagataaca acatgcagat gtacagaccc 5760
tcctggcatc atatcgcaaa attatggaga agctgtatcc ctgatagata gacactcgtg 5820
caatgtctta tcattagacg gcataactct gaggctcagt ggggaatttg atgcaactta 5880
tcaaaagaac atctcaatat tagattctca ggtcatcgtg acaggcaatc ttgatatatc 5940
aactgaactt ggaaacgtca ataattcgat cagcaatgcc ttggacaagt tggcagaaag 6000
caacagcaaa ctagaaaaag tcaacgtcag actaactagc acatccgctc tcattaccta 6060
tattgttcta actgtcattt ccctaatttt cggtgcactt agtctggttt tagcgtgtta 6120
cctgatgtac aagcagaagg cacaacaaaa gaccctgtta tggcttggga acaataccct 6180
cgatcagatg agagccacca tgagagcatg aatgcaaata ggaagtggac ggacacccaa 6240
cggcagcccg tgtgtcaatt ccgataacct gtcaagtagg agacttaaga aaaaattact 6300
gggaacaagc aaccaaagag caatacacgg gtagaacggt cagaggagcc acccttcaat 6360
tgaaaattag gcttcacaac atccgttcta ccacaccacc aacaacaaga gtcaatcatg 6420
gaccgcgtgg ttaacagagt catgctggag aatgaagaaa gagaagcaaa gaacacatgg 6480
cgcttagttt tccggatcgc agtcttattt ttaatggtaa tgattctagc tatctctgcg 6540
gctgccctgg catacagcat ggaggccagt acgccacacg acctcgcagg catatcgact 6600
gtgatctcca agacagaaga taaggttacg tctttactca gttcaagcca agatgtgata 6660
gataagatat acaagcaggt agctcttgaa tccccgctgg cactattaaa caccgaatct 6720
gtaattatga atgcaataac ctctctttct tatcaaatta acggggctga gaacagtagc 6780
ggatgcggtg cgcccgttca tgacccagat tatatcgggg ggataggcaa agaactcata 6840
gtggacgaca ttagtaatgt cgcatcattt tatccttctg catatcaaga acacttgaat 6900
ttcatcccgg cacctactac aggatctggt tgcactcgga taccctcatt tgacatgggc 6960
accacccatt attgttatac tcacaatgtg atactatctg gttgcagaga tcactcacac 7020
tcacatcaat acctagcact tggtgtgctt cggacatctg caacagggag ggtattcttt 7080
tctactctgc gctccatcaa tttagatgac actcaaaatc ggaagtcttg cagtgtgagt 7140
gcaacccctt taggttgtga tatgctgtgc tctaaggtca cagggactga agaggaggat 7200
tacaagtcag ttgcccccac atcaatggtg cacggaaggc taggatttga cggtcaatac 7260
catgagaaag acttagacac cacggtctta tttaaggatt gggtggcaaa ttacccgggg 7320
gtgggaggag ggtcttttat tgacggccgt gtatggttcc cagtttacgg agggctcaaa 7380
cctaattcac ccagtgacat cgcacaagaa gggaaatatg taatatacaa gcgccataat 7440
aacacatgcc ccgataaaca agattaccaa attcggatgg ctaagtcctc atataaacct 7500
gggcgatttg gtggaaagcg cgtacagcaa gctatcctat ctatcaaagt gtcaacatcc 7560
ctgggtaagg acccggtgct gactattcca cctaatacaa tcacactcat gggagccgaa 7620
ggcagaatcc tcacagtagg gacatctcac ttcttgtatc aacgagggtc ttcatatttc 7680
tcccctgcct tattgtatcc catgacagta agtaacaaaa cggctacact ccatagtcct 7740
tacatgttta atgctttcac tcggccaggt agtgtccctt gccaggcatc agcaaggtgc 7800
cccaactcat gcatcactgg ggtctatacc gatccatatc ccttaatctt ctataggaat 7860
catactctac gaggggtctt cgggacgatg cttgatgatg aacaagcgag gcttaacccc 7920
gtatctgcag tatttgacaa catatctcgc agtcgtgtca cccgggtgag ttcaagcaac 7980
accaaggcag catacacgac atcgacatgt tttaaagttg tcaagactaa taaagtttat 8040
tgtcttagta tcgcagaaat atccaatacc ctattcgggg aatttaggat cgttcccttg 8100
ctagttgaga tcctcaaaga tgatagagtt taagaagcta gacttggccg attgagccaa 8160
tcataggatg gttgggagga cgacattgcg ccaatcatct cccataatgc ttagagtcaa 8220
gctgaacatt agcataaatc aggatcccgt gttgttgggc aaccgcaatc cgacaatgct 8280
gacatgattg ttctgagtct cgctcactgt cactttatta agaaaaaaca caagaagcat 8340
tgacatataa gggaaaataa ccaacaagag agaacacggg taggacatgg cgggctccgg 8400
tcctgagagg gcagagcacc agatcatcct accagagtca catttatcct ctccattggt 8460
caagcacaaa ttgttatact actggaaatt aaccgggcta ccgcttcctg atgaatgcga 8520
ctttgatcat ctcattatca gcaggcaatg gaagagaata ctggagtcag ccactcctga 8580
cacagagaga atgataaaac ttgggcgggc ggtgcaccag actctcaacc acaattccaa 8640
gatgactgga gtgctccatc ccaggtgttt agaagaactg gctagtattg aggtccctga 8700
ttcaactaac aaattccgga agattgaaaa gaagatccag attcacaaca caagatatgg 8760
agacctgttc acaaagctgt gcgtgcaagt tgagaagaaa ttgctagggt catctctgtc 8820
taataatgtc ccacgatcag aggaattcaa cagcatccgt acagatccgg cattctggtt 8880
tcactcaaaa tggtccagag ccaagttcgc gtggctccat ataaaacaag tccaaaggca 8940
tctgattgta gcagcaagga caaggtctgc agtcaacaag ttagtaacat taaatcataa 9000
gataggccat gtctttatta ctcctgagct tgtcattgtg acacacacag acgagaacaa 9060
gttcacatgt ctcacccagg aacttgtatt gatgtatgcg gatatgatgg aaggcaggga 9120
catggtcaat ataatatctt ctacagcagc acatctcagg aacctatccg agaaaattga 9180
tgatattctg cggttagtag atgctctggc aaaggactta ggtaatcaag tctatgatgt 9240
tgtagcatta atggagggat ttgcatacgg tgccgttcag ctgcttgagc catcaggtac 9300
atttgcagga gatttctttg catttaacct acaggagctc aaaaacacgt taatcgaact 9360
tctccccaat aatatagcgg aagcagtaac tcacgctatt gccactgtat tctctggatt 9420
agaacagaac caagcagctg agatgttgtg cttgctgcgt ttgtggggtc atccattgct 9480
tgagtctcgt agtgcagcaa gagcagtcag gagccagatg tgcgcaccaa agatggtaga 9540
ctttgatatg atcctccagg tattatcttt ctttaaagga acaatcatca atggatacag 9600
aaaaaagaac tcaggtgtgt ggccacgcgt caaagtagat acaatatatg gaaatatcat 9660
tgggcagcta catgctgatt cagcagagat ctcacatgat gtcatgttga gggagtacaa 9720
gagtttatcc gctcttgaat ttgagccatg tatagattat gaccctgtta ccaatctaag 9780
catgttccta aaagacaagg caatcgcaca tcctagtgat aactggctcg cctcatttag 9840
gcggaaccta ctctctgagg accagaagaa acagataaag gaggcaactt caactaaccg 9900
cctcctgata gagttcttag aatcaaatga ttttgatcca tataaagaaa tggaatacct 9960
gacaaccctc gagtacctaa gagatgacag tgtggcagta tcgtactcac tcaaagagaa 10020
agaggtgaaa gtgaatggac ggatttttgc taaattaaca aagaaactaa ggaattgcca 10080
ggtaatggca gaaggaattc tagctgacca gattgcacct ttcttccagg gaaatggggt 10140
cattcaagat agcatatcct tgacaaagag tatgttagca atgagtcaac tgtcctttaa 10200
cagcaataag aaacgtatcg ctgactgcaa agagagggtt tcctcaaacc gcaatcatga 10260
tcccaagagc aagaatcgta gaagagttgc cacctttatc acgactgacc tacaaaagta 10320
ttgtcttaac tggagatatc agacagtcaa actattcgcc catgccatca atcagctgat 10380
gggcctacct catttctttg agtggattca tcttaggctg atggacacta caatgtttgt 10440
aggggatcct ttcaatcctc caagtgaccc gaccgactgt gatctatcaa gagtcccaaa 10500
tgatgatata tatattgtca gtgctagagg gggcattgag ggactctgtc agaagctatg 10560
gacgatgatc tcaattgctg caatccaact tgccgcagca agatctcatt gtcgagttgc 10620
ctgcatggta caaggtgaca atcaagtaat agctgtaacg agagaggtga gatcagatga 10680
ttccccggat atggtattga cgcagttgca tcaggctagt gataatttct tcaaggaatt 10740
gattcatgtc aatcatctga ttggccataa cctgaaggat cgtgaaacca ttagatcaga 10800
cacattcttc atatacagca aacgaatatt caaagatgga gcaatactca gtcaggtcct 10860
caaaaattca tctaaattgg tgctaatatc aggtgacctt agcgaaaaca ctgtaatgtc 10920
ctgtgccaac attgcatcca ctgtagcacg actatgtgag aatgggcttc ctaaggactt 10980
ctgttactat ttgaactacc taatgagttg cgtgcagaca tattttgatt cagagttttc 11040
tattactcac agctcacagt cagattccaa ccagtcctgg attgaggata tctctttcgt 11100
acactcatac gtgttaaccc ctgcccaact ggggggactg agtaaccttc aatactcaag 11160
gctctacaca aggaatattg gcgacccagg gaccactgcc tttgcagagg tcaagcgact 11220
agaagcagtg gggttgttga gtcccagcat catgactaac atcttaacca ggccacctgg 11280
caatggagat tgggccagcc tatgcaacga cccatactct tttaattttg agactgttgc 11340
aagcccaaat attgtcctca agaaacatac acagaaagtc ctatttgaga catgttcaaa 11400
ccctttatta tccggggtac atacagagga caatgaggca gaagagaaag cattggctga 11460
attcttactc aatcaagaag tgattcaccc acgtgtcgca catgctatca tggaagcaag 11520
ctctgtgggt aggagaaagc aaattcaagg gcttgttgac acaacgaaca ctgtgattaa 11580
gattgcactg actaggaggc ccctcggtat caaaagactg atgcggataa tcaattactc 11640
aagcatgcat gcaatgttgt tcagggatga tattttctta tccactagat ccaaccaccc 11700
attagtttct tctaatatgt gctcgctgac gctagcagat tatgctcgga acagaagctg 11760
gtcacccctg acagggggca ggaaaatact gggtgtatcc aaccccgata ccatagaact 11820
tgtggaggga gagattctca gcgtcagtgg agggtgcaca aaatgtgaca gcggagatga 11880
gcagtttact tggttccatc ttccaagcaa tatagagttg actgatgaca ccagcaaaaa 11940
tcccccgatg agagtgccat atctcgggtc gaagactcaa gagagaagag ccgcctcact 12000
tgcgaaaata gcccatatgt caccacatgt gaaagcagca ctaagggcat catccgtgtt 12060
aatctgggct tatggggaca atgaagtgaa ctggactgct gctcttaata ttgcaaggtc 12120
tcgatgcaac ataagctcag agtatcttcg gctattgtca cccctgccca cagctgggaa 12180
tctccaacat agattggatg atggcataac ccagatgaca tttacccctg catctctcta 12240
cagagtgtcg ccttacattc acatatccaa tgattctcaa aggctgttca ccgaagaagg 12300
ggtcaaagag ggaaacgtgg tttaccagca aattatgctc ttgggtttat ctctaattga 12360
gtcactcttc ccaatgacaa caaccagaac atacgatgag atcacattac acctccacag 12420
taaatttagc tgctgtatcc gagaagcgcc tgtcgcagtt cctttcgagc tcctcggact 12480
ggtaccggaa ttaaggatgg taacctcaaa taagttcatg tatgatccta gccctatatc 12540
agagagggat tttgcgagac ttgacttagc tatattcaag agttatgagc ttaacttgga 12600
atcatatccc acgctggagc taatgaacat tctttcgata tctagcggga aattgattgg 12660
ccaatctgtg gtttcttatg atgaagatac ttctataaag aatgatgcta taatagtgta 12720
tgacaacaca cggaattgga ttagtgaggc acagaactca gatgtggtcc gcctgtttga 12780
gtatgcagca ctcgaagtgc tcctcgactg tgcttatcaa ctctactatc tgagggtaag 12840
gggtctaaac aacatcgtcc tatacatgaa tgacttatat aagaacatgc cagggatcct 12900
actctccaat attgcagcca cgatatccca ccccctcatt cactcaaggt tgaatgcagt 12960
aggtctaatt aatcatgacg ggtcacacca gcttgcagat atagactttg tcgaggtgtc 13020
tgcgaaattg ttagtctcct gcactcgacg cgtggtctca ggtttatatg cagggagtaa 13080
gtatgatctg ctgtttccat ctgtcttaga tgataacctg aatgagaaga tgcttcaact 13140
aatttcccgg ttatgctgct tgtacacagt gctctttgct acaacaagag aaatcccaaa 13200
aataaggggc ctatcagcag aagagaaatg ctcaatactc actgagtatc tattgtcgga 13260
tgctgtaaaa ccgttgctta ggtccgaaca attgagttct atcatgtctc ccaacataat 13320
cacgttccca gccaatctat actacatgtc taggaagagc cttaatttga tcagagaacg 13380
agaggacaga gatactatct tgtcgttgtt gttccctcag gagtcactgc ttgagcttcg 13440
cccagtacgg gacattggtg ctcgagtgaa agacccgttt acccgacaac ccgcatcttt 13500
catacaagag ctggatctga gtgccccagc aaggtacgac gcgtttacac tgagtaagat 13560
ttgcttcgag cacacactac cgaacccaag ggaagattac ctagtacgat acttgttcag 13620
aggagtaggg actgcttcat cttcttggta taaggcgtct catcttctat ccatatctga 13680
ggttaggtgt gcaagacatg ggaactcttt atacttagcg gaaggaagcg gagccatcat 13740
gagtcttctt gaattgcata taccacatga gaccatctat tacaatacac ttttctcgaa 13800
tgagatgaac cctccacagc ggcatttcgg acctacacca acacagtttc taaactcggt 13860
cgtttatagg aatctacaag cggaagtgcc atgtaaagat ggatatgtcc aggagttcta 13920
tccattatgg agagagaatg cagaagaaag tgatctgacc tcagataagg cagttggata 13980
tatcacatct gtagtaccct acaggtctgt atcattacta cattgtgaca ttgagattcc 14040
tccagggtcc agtcaaagct tattagatca actggctact aatttatccc tgattgccat 14100
gcattctgtg agagagggcg gggtagtgat catcaaggta ctgtatgcaa tggggtacta 14160
cttccactta ctcatgaatt tattcactcc atgttccacg aaaggataca tactttccaa 14220
tggctacgcc tgtagagggg atatggagtg ttacctgata ttcgttatgg gctgcttagg 14280
cgggcccact ttcgtgcacg aagtggtaag gatggcaaaa gctctaatac aacgacacgg 14340
tacacttcta tctaaatcag atgaaatcac attgactaag ctatttacct cacagcagcg 14400
tcgtgtaaca gatctcctat ccagcccttt accgaagcta atgaggctct taagtgaaaa 14460
cattgatgct gcactaattg aagccggggg acagcccgtc cgtccatttt gtgcagaaag 14520
tttggtgagc acactaacaa atacgaccca gacaactctg atcattgcca gccacattga 14580
cacagtcatc cggtccgtga tttacatgga ggctgagggt gacctcgccg acacagtgtt 14640
cttattaact ccttacaatc tatccacaga cggtaaaaag agaacatcac ttaagcagtg 14700
caccaaacag atcttggaag tcacaatatt gggtctcaga gccaaagaca tcaataaaat 14760
aggtgatgta atcagcttag tactcagagg tgcgatttcc ctagaggacc tcatcccatt 14820
aaggacatac ctgaagcaca gtacctgtcc taaatacctg aaagcggtcc taggtattac 14880
taagctcaaa gaaatgttca caggtacttc gttattgtac ttgactcgcg ctcaacaaaa 14940
attctacatg aaaactatag gtaatgctgc caagggatat tacagtaata atgactctta 15000
aaggcaatcg tacaccaatc agttatcttc ttaactgatg actccctcat tgacttgatt 15060
ataccagatt agaaaaaagt taaattctga ctctttggaa ctcgtattcg gattcagtta 15120
gttaacttta agcaaaaatg cgcaaagtcg tctctaatca cagctatgtc attcaccaaa 15180
tctctgtttg gt 15192
<210> 3
<211> 56
<212> DNA
<213> 人工序列()
<400> 3
cacccccagc cacacgaccc catccacccg ggacaacaca ggcacagctc ggccag 56
<210> 4
<211> 49
<212> DNA
<213> 人工序列()
<400> 4
ctataaggcg cccctgtctc cctcctccgg acgtggatac agacccttg 49
<210> 5
<211> 46
<212> DNA
<213> 人工序列()
<400> 5
gagggagaca ggggcgcctt ataggtgctg ttattggcag tgtagc 46
<210> 6
<211> 49
<212> DNA
<213> 人工序列()
<400> 6
cttggtgttg cttgaactca cccgggtgac acgactgcga gatatgttg 49
Claims (5)
1.一株基因VII型NDV突变型重组病毒rDHN3-mF,其特征在于,其序列如序列表SEQ IDNO:1所示。
2.一株VII型NDV突变型感染性克隆pBR322-DHN3-mF的制备方法,其特征在于,包括如下步骤:
步骤1:将质粒pBR322-DHN3采用SmaI酶切,得到酶切后的质粒;
步骤2:采用引物change-F1-F、change-F1-R和change-F2-F、change-F2-R以质粒pBR322-DHN3为模板扩增目的片段,得到PCR扩增产物;
步骤3:将酶切后的质粒和PCR扩增产物在重组酶的作用下同源重组,获得含mF的质粒pBR322-mFDHN3;
其中,质粒pBR322-DHN3为人工重组得到的DHN3全基因组重组入载体质粒中得到全基因组表达载体;所述DHN3全基因组的序列如序列表SEQ ID NO:2;
引物change-F1-F的序列如序列表SEQ ID NO:3;
引物change-F1-R的序列如序列表SEQ ID NO:4;
引物change-F2-F的序列如序列表SEQ ID NO:5;
引物change-F2-R的序列如序列表SEQ ID NO:6;
步骤4:采用转染试剂转染BHK-21细胞获得含病毒DHN3-mF的病毒液;所述转染试剂包含pBR322-mFDHN3 4μg,pXJ40-NP 2.5μg,pXJ40-P 1.25μg,pXJ40-L 1.25μg,pXJ40-DE3 3μg;
其中,辅助质粒pXJ40-NP、pXJ40-P、pXJ40-L的目标片段分别为NP基因、P基因、L基因,载体为pXJ40;
所述NP基因在序列表SEQ ID NO:2中位置为1-1591nt;P基因在序列表SEQ ID NO:2中位置为1925-3109nt;L基因在序列表SEQ ID NO:2中位置为8166-15192nt。
3.根据权利要求2所述的基因VII型NDV突变型感染性克隆pBR322-DHN3-mF的制备方法,其特征在于,所述步骤1具体为:用SmaI酶切质粒pBR322-DHN3,通过0.8%琼脂糖凝胶电泳回收酶切后的质粒待用,酶切后的质粒的大小为13399bp。
4.根据权利要求2所述的基因VII型NDV突变型感染性克隆病毒DHN3-mF的制备方法,其特征在于,所述步骤3具体为:将BHK-21细胞培养于6孔板中,次日细胞长至80%左右满,转染前30min用PBS清洗细胞3次,最后一次弃除PBS后每孔加入1ml Opti-MEM,将6孔板放回37℃5%CO2培养箱中继续培养,同时用赛默飞Lipofectamine LTX DNA TransfectionReagents转染试剂按照试剂说明配制如下转染液:
A液:Opti-MEM Medium 150μl,Lipofectamine LTX Reagent 15μl,静置5min;
B液:Opti-MEM DNA 175μl其中pBR322-mFDHN3 4μg,pXJ40-NP 2.5μg,pXJ40-P 1.25μg,pXJ40-L 1.25μg,pXJ40-DE3 3μg,PLUS Reagent 3.5μl,吹打混匀,静置5min;
取A液,B液各150μl混合均匀,静置20min得到混合液;
取250μl混合液加入细胞培养液中,轻轻混匀,置37℃5%CO2培养,8h后弃除培养液,用PBS清洗3次后加含5%SPF鸡胚尿囊液和0.1%胰酶的DMEM培养液继续置37℃5%CO2培养,4天后收获细胞置-80度冻存,在使用时,进行2-3次冻融后离心取上清液即可得到所述含病毒rDHN3-mF的病毒液。
5.一种疫苗,其特征在于,含有灭活的如权利要求1所述的基因VII型突变型重组病毒rDHN3-mF。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010499879.4A CN112159799A (zh) | 2020-06-04 | 2020-06-04 | 一种NDVVIId突变型感染性克隆病毒DHN3-mF及其制备方法和疫苗 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010499879.4A CN112159799A (zh) | 2020-06-04 | 2020-06-04 | 一种NDVVIId突变型感染性克隆病毒DHN3-mF及其制备方法和疫苗 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112159799A true CN112159799A (zh) | 2021-01-01 |
Family
ID=73859516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010499879.4A Pending CN112159799A (zh) | 2020-06-04 | 2020-06-04 | 一种NDVVIId突变型感染性克隆病毒DHN3-mF及其制备方法和疫苗 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112159799A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104988124A (zh) * | 2015-05-07 | 2015-10-21 | 中国农业科学院兰州兽医研究所 | 基因vii型新城疫病毒标记疫苗株及其应用 |
CN107630008A (zh) * | 2016-07-14 | 2018-01-26 | 中国农业大学 | 基因ⅶ型新城疫病毒标记疫苗株及其应用 |
WO2018209194A2 (en) * | 2017-05-12 | 2018-11-15 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
EP3552608A1 (en) * | 2018-04-09 | 2019-10-16 | Rapo Yerape B.H. Ltd | Increased activity of oncoloytic newcastle disease virus |
CN110592108A (zh) * | 2019-09-20 | 2019-12-20 | 华农(肇庆)生物产业技术研究院有限公司 | 一种针对ii类vii型流行ndv株dhn3的感染性重组克隆方法 |
-
2020
- 2020-06-04 CN CN202010499879.4A patent/CN112159799A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104988124A (zh) * | 2015-05-07 | 2015-10-21 | 中国农业科学院兰州兽医研究所 | 基因vii型新城疫病毒标记疫苗株及其应用 |
CN107630008A (zh) * | 2016-07-14 | 2018-01-26 | 中国农业大学 | 基因ⅶ型新城疫病毒标记疫苗株及其应用 |
WO2018209194A2 (en) * | 2017-05-12 | 2018-11-15 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
EP3552608A1 (en) * | 2018-04-09 | 2019-10-16 | Rapo Yerape B.H. Ltd | Increased activity of oncoloytic newcastle disease virus |
CN110592108A (zh) * | 2019-09-20 | 2019-12-20 | 华农(肇庆)生物产业技术研究院有限公司 | 一种针对ii类vii型流行ndv株dhn3的感染性重组克隆方法 |
Non-Patent Citations (2)
Title |
---|
KATTENBELT JA 等: "Sequence variation in the Newcastle disease virus genome", 《VIRUS RES》 * |
王泽仁 等: "鸡新城疫病毒HN68/09株的鉴定及其F基因的分子特征", 《西南农业学报》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111560354B (zh) | 重组新型冠状病毒及其制备方法和应用 | |
CN104962581B (zh) | 一种表达非洲猪瘟病毒p72蛋白的重组病毒疫苗株 | |
WO2020258757A1 (zh) | 一种突变株3型鸭甲肝病毒ch-p60-117c株及构建方法 | |
CN108728419A (zh) | 表达禽腺病毒penton蛋白重组新城疫疫苗候选株rAI4-penton及构建方法 | |
US11744888B2 (en) | Method of treating or preventing clinical signs caused by infectious bronchitis virus with 4/91 IBV vaccine having heterologous spike protein | |
CN109321535A (zh) | 一种热稳定的新城疫病毒弱毒疫苗候选株 | |
CN104195116B (zh) | 一种表达鹅细小病毒vp3基因的重组新城疫病毒及其构建方法 | |
CN106520710A (zh) | 表达鸭坦布苏病毒prm和E蛋白重组新城疫病毒活载体疫苗的制备及应用 | |
CN110680912B (zh) | H3n2和h3n8亚型犬流感二价灭活苗及其制备方法与应用 | |
Ruan et al. | Generation and evaluation of a vaccine candidate of attenuated and heat-resistant genotype VIII Newcastle disease virus | |
CN116926022B (zh) | 一种鸽源基因Ⅵ型新城疫病毒mGZ08、用途、制备方法、培养方法、疫苗 | |
US11696947B2 (en) | H52 IBV vaccine with heterologous spike protein | |
CN109136200A (zh) | 一种重组传染性造血器官坏死病毒及其构建方法与应用 | |
CN110904056B (zh) | 一种传染性支气管炎病毒rH120-YZS1Δ5a及其构建方法和应用 | |
CN104830811A (zh) | H9n2亚型禽流感病毒ns1基因缺失减毒活疫苗候选株及其构建方法和应用 | |
CN112063596A (zh) | 鸽副黏病毒1型ppmv-1/bj-c株及其应用 | |
CN109943576A (zh) | 一种嵌合犬瘟热病毒主要免疫基因的重组狂犬病病毒及其应用 | |
CN110499296A (zh) | 一种耐热的血清8b型禽腺病毒基因工程疫苗候选株及其构建方法 | |
CN110331135A (zh) | 表达基因vii型新城疫病毒融合蛋白的重组火鸡疱疹病毒候选疫苗株及制备方法 | |
CN116121206A (zh) | 一种ⅺ型新城疫病毒(f48e9)的重组拯救病毒制备方法、重组病毒及应用 | |
CN111647610B (zh) | 一种互换ha和ns1缺失基因包装信号的h9n2亚型禽流感病毒及其构建方法和应用 | |
CN112159799A (zh) | 一种NDVVIId突变型感染性克隆病毒DHN3-mF及其制备方法和疫苗 | |
CN110484515B (zh) | 一种预防FAdV-4和NDV的疫苗载体及其制备方法及应用 | |
KR102027367B1 (ko) | 저온적응 전염성 기관지염 바이러스 및 이를 이용한 백신 조성물 | |
CN111926025B (zh) | 一株经过密码子替换的基因ⅶ型新城疫病毒的拯救方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210101 |
|
RJ01 | Rejection of invention patent application after publication |